Burnet is working on ways to slow the detrimental biological process of 'inflammageing', the build-up of low-grade inflammation in the body, increasing the risk of age-related conditions. Our researchers discovered that the release of a certain cytokine transforms B cells into overactive aged B cells. Our models could pave the way for therapeutics that slow or prevent inflammageing’s impact.
This flyer contains information about the process of inflammageing and its impact on immune response, our technology and models to screen therapeutics, and our track record in T and B cells and models of immunodeficiency.